The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer
Authors:
- Mariana HirataMariana Hirata
- Rogerio Padovan GonçalvesRogerio Padovan Gonçalves
- Maria Eduarda Teixeira Pereira Cândido da SilvaMaria Eduarda Teixeira Pereira Cândido da Silva
- Geovanna de Castro FeitosaGeovanna de Castro Feitosa
- Caio Sérgio Galina SpillaCaio Sérgio Galina Spilla
- Domingos Donizeti RoqueDomingos Donizeti Roque
- Lisete Horn Belon FernandesLisete Horn Belon Fernandes
- Virgínia Maria Cavallari Strozze CatharinVirgínia Maria Cavallari Strozze Catharin
- Vitor Cavallari Strozze CatharinVitor Cavallari Strozze Catharin
- Leila Maria Guissoni CamposLeila Maria Guissoni Campos
- Ana Luiza Decanini Miranda de SouzaAna Luiza Decanini Miranda de Souza
- Eliana de Souza Bastos Mazuqueli PereiraEliana de Souza Bastos Mazuqueli Pereira
Open Access
- 10 March 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 340
Abstract
Background/Objectives: Breast cancer is a biologically complex malignancy whose high prevalence and therapeutic resistance represent a continuous challenge for global health. The Tumor Microenvironment (TME) is a crucial component in disease progression, and the Extracellular Matrix (ECM), particularly its 3D collagen architecture, is recognized for mediating interactions that influence invasion, metastasis, and pharmacological response. This review aims to critically synthesize recent evidence to elucidate the multifaceted role of collagen in the progression and modulation of therapeutic response in breast adenocarcinoma. Methods: A comprehensive literature review was conducted, analyzing studies addressing specific collagen subtypes, ECM stiffening (fibrosis), biomechanical signaling, and their impact on drug transport kinetics and immunomodulatory effects. Results: The results demonstrate that structural alterations of collagen not only orchestrate a pro-tumoral microenvironment, fostering aggressive phenotypes and immune evasion, but also create a physical barrier that compromises drug delivery efficiency and promotes metastatic dissemination. The synthesis of the data reinforces collagen as a potent prognostic biomarker and a promising therapeutic target for overcoming stroma-mediated resistance. Conclusions: Targeting the collagen-rich stroma and its 3D network is a critical frontier for therapeutic innovation. Developing adjuvant strategies to modulate the ECM has the potential to enhance clinical outcomes and optimize the distribution of antineoplastic agents, especially in patients with high degrees of tumor fibrosis.Keywords
All Related Versions
This publication has 97 references indexed in Scilit:
- Mucinous breast cancer organoids: an in vitro research modelDiscover Oncology, 2025
- Epigenetic dynamics and molecular mechanisms in oncogenesis, tumor progression, and therapy resistanceNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Effectiveness and safety of the modified multiple mode procedures versus traditional multiple mode procedures on treating facial atrophic acne scars: a propensity score matching retrospective cohort studyLasers in Medical Science, 2024
- Therapeutic efficiency of Tamoxifen/Orlistat nanocrystals against solid ehrlich carcinoma via targeting TXNIP/HIF1-α/MMP-9/P27 and BAX/Bcl2/P53 signaling pathwaysBiomedicine & Pharmacotherapy, 2024
- Rat Models of Hormone Receptor-Positive Breast CancerJournal of Mammary Gland Biology and Neoplasia, 2024
- Decellularized extracellular matrix mediates tissue construction and regenerationFrontiers of Medicine, 2021
- The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma PatientsThe American Journal of Pathology, 2018
- Extracellular matrix components in breast cancer progression and metastasisThe Breast, 2013
- Stromal cells in tumor microenvironment and breast cancerCancer and Metastasis Reviews, 2012
- Aligned Collagen Is a Prognostic Signature for Survival in Human Breast CarcinomaThe American Journal of Pathology, 2011